Anavex Blarcamesine Slows Cognitive Decline in Early Alzheimer’s Patients
Anavex Life Sciences (Nasdaq: AVXL) continues to make strides in developing therapeutics for neurodegenerative diseases, including Alzheimer’s disease (AD), with its lead drug candidate, ANAVEX 2-73 (blarcamesine). In a recent pivotal study, the drug demonstrated significant benefits in slowing cognitive decline in patients with early Alzheimer’s, marking a major step forward in the treatment of…